# Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026
Canonical URL: https://biopharmsignal.com/news/FHTX/foghorn-therapeutics-to-participate-in-the-goldman-sachs-47th-annual-global-healthcare-conference-2026
Ticker: FHTX
Company: Foghorn Therapeutics
Source: Foghorn Therapeutics
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.foghorntx.com
## Summary

WATERTOWN, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the

## Article Body
WATERTOWN, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the
## Recent Company News
- 2026-06-25 13:46 EST — [Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026](https://biopharmsignal.com/news/FHTX/foghorn-therapeutics-to-participate-in-the-goldman-sachs-47th-annual-global-healthcare-conference-2026) — Source: Foghorn Therapeutics
- 2026-06-25 13:46 EST — [Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May](https://biopharmsignal.com/news/FHTX/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-in-may) — Source: Foghorn Therapeutics
- 2026-06-25 13:46 EST — [Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update](https://biopharmsignal.com/news/FHTX/foghorn-therapeutics-provides-first-quarter-2026-financial-and-corporate-update) — Source: Foghorn Therapeutics
- 2026-06-25 13:46 EST — [Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update](https://biopharmsignal.com/news/FHTX/foghorn-therapeutics-provides-third-quarter-2025-financial-and-corporate-update) — Source: Foghorn Therapeutics
- 2026-06-25 13:46 EST — [Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference](https://biopharmsignal.com/news/FHTX/foghorn-therapeutics-to-participate-in-the-8th-annual-evercore-healthcare-conference) — Source: Foghorn Therapeutics
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)